Neopharm Group and GW Pharmaceuticals plc announced that Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray) has received regulatory approval from the Israeli Ministry of Health for the treatment of spasticity and neuropathic pain due…
![](/wp-content/themes/Neopharm_Group_EN/images/generic.jpg)
![](/wp-content/themes/Neopharm_Group_EN/images/generic.jpg)
Neopharm Group Celebrates 70 years of Leadership and Innovation
January 2, 2012![](https://neopharmgroup.com/wp-content/uploads/2012/01/search.jpg)
Welcome to the New Neopharm Group website
January 1, 2012![](https://neopharmgroup.com/wp-content/uploads/2011/12/growth-150x150.jpg)